Emergent BioSolutions | EBS - Loan Capital


Emergent BioSolutions reported $446.5M in Loan Capital for its fiscal quarter ending in December of 2023.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Akebia Therapeutics USD 36.39M 11.85M Mar/2026
ALKERMES USD 1.48B 1.2B Mar/2026
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
ANI Pharmaceuticals USD 286M 5.84M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Coherus Biosciences USD 51.08M 496K Dec/2025
Emergent BioSolutions USD 446.5M 1.7M Dec/2023
Glaxosmithkline GBP 19.82B 203.13M Dec/2025
Heron Therapeutics USD 140.64M 975K Dec/2025
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Lexicon Pharmaceuticals USD 49.68M 276K Mar/2026
Lonza CHF 3.88B 323M Dec/2025
Merck USD 46.67B 77M Mar/2026
Moderna USD 603M 7M Mar/2026
Myriad Genetics USD 120.3M 400K Mar/2026
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pacira USD 367.66M 4.53M Mar/2026
Pfizer USD 60.57B 1.08B Mar/2026
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Sanofi EUR 13.84B 1.88B Mar/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
United Therapeutics USD 100M 100M Jun/2024
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024
Xoma USD 94.38M 7.82M Sep/2025